Crospovidone XL 10 is a crosslinked polyvinylpyrrolidone used primarily as a superdisintegrant in pharmaceutical tablets. I use this type of excipient to help a compressed tablet break apart rapidly when it contacts aqueous gastrointestinal fluid, allowing the active pharmaceutical ingredient to become available for dissolution. It is especially relevant in immediate-release tablets, orally disintegrating formulations, and other products where reliable tablet breakup is important.
If you want to learn more, please visit our website.
In practical formulation work, crospovidone XL 10 is not the drug itself and does not replace the active ingredient. Its role is to support tablet performance by promoting liquid penetration and particle separation without dissolving like an ordinary water-soluble binder. The exact loading, processing method, and suitability must be confirmed through formulation development, finished-product testing, and applicable regulatory requirements.
Crospovidone is a crosslinked form of polyvinylpyrrolidone, also known as crosslinked PVP. Because the polymer is crosslinked, it is generally insoluble in water while remaining capable of absorbing liquid and supporting rapid tablet disintegration. “XL 10” is a grade designation used in the market, but the meaning of the designation and the associated specification must be confirmed against the individual supplier’s technical documentation.
From a formulation perspective, I treat Crospovidone XL 10 as a functional excipient rather than as a universal performance guarantee. Its behavior can change with particle size, porosity, compression force, lubricant concentration, granulation method, and the properties of the active ingredient. For this reason, a buyer should request the current specification and review representative samples before approving a commercial supply.
The primary use of Crospovidone XL 10 is to accelerate tablet disintegration. When fluid enters the tablet matrix, the crospovidone particles can take up liquid and contribute to the breakup of the compact. This process helps expose more surface area of the active pharmaceutical ingredient for the next stage of dissolution.
Unlike a conventional soluble binder, crospovidone is designed to retain its particulate structure during liquid contact. This characteristic can be useful when a formulator needs rapid tablet breakup without adding a large amount of a material that forms a viscous solution. However, the actual disintegration result depends on the complete formulation and should be demonstrated using the finished tablet.
In an immediate-release tablet, the formulation objective is normally to release the active ingredient without an intentionally prolonged release mechanism. Crospovidone XL 10 may support this objective by helping the tablet lose its compact structure after wetting. It does not, by itself, determine dissolution rate, bioavailability, or therapeutic effect.
I therefore recommend evaluating disintegration and dissolution together. A tablet may disintegrate quickly but still dissolve slowly if the active ingredient has poor wettability, large particle size, low solubility, or strong crystal lattice energy. Crospovidone should be selected as one part of a broader formulation strategy.
Crospovidone can contribute to a balance between tablet mechanical strength and disintegration behavior, but the outcome is formulation-specific. Excessive compression, over-lubrication, or an unsuitable granulation process may reduce liquid penetration even when the selected superdisintegrant is appropriate. I use development trials to identify a practical operating window rather than assuming that a higher excipient level will always improve performance.
Crospovidone XL 10 is commonly considered for immediate-release tablets containing chemical active ingredients, direct-compression blends, and wet-granulated formulations. It may also be evaluated in orally disintegrating or fast-disintegrating products when the formulation requires rapid breakup in a small amount of liquid. The final suitability depends on the dosage form, target disintegration specification, taste considerations, compression process, and regulatory status of the product.
For a 500 mg tablet, a development level of 2% w/w would equal approximately 10 mg of crospovidone per tablet. A broader initial screening range might be 1% to 5% w/w, equivalent to 5 mg to 25 mg in the same 500 mg tablet, but these figures are development examples rather than a guaranteed recommendation for every product.
Manufacturers may add part of the crospovidone during granulation and the remainder during final blending. Intragranular addition can support disintegration within granules, while extragranular addition may help the final tablet break apart more efficiently. The best approach should be established through comparative trials using the actual formulation and equipment.
Yuking Product Page
When comparing crospovidone products, I distinguish between the chemical identity and the physical grade. Different grades may vary in particle-size distribution, bulk density, flow behavior, moisture content, and surface characteristics. These differences can influence blending, die filling, tablet weight variation, and disintegration.
Buyers should also compare whether the material is intended for direct compression, granulation, or a combination process. A product that performs well in one process may not deliver the same result in another because granule structure and compression conditions affect liquid access. If a supplier offers several particle-size options, the choice should be based on trials rather than on the grade name alone.
| Evaluation area | Why it matters | What I recommend requesting |
|---|---|---|
| Identification and assay-related information | Confirms material identity and batch conformity | Current specification, certificate of analysis, and test methods |
| Particle-size distribution | Affects flow, blending, and tablet disintegration behavior | Defined particle-size data and sampling method |
| Moisture or loss on drying | Can influence compression and storage stability | Release limit, test result, and recommended storage conditions |
| Microbial and contamination controls | Important for pharmaceutical excipient qualification | Applicable quality documentation and change-control information |
| Packaging and shelf-life | Protects material quality during transport and storage | Packaging format, retest or expiry information, and handling guidance |
These parameters should be reviewed against the buyer’s internal requirements and the relevant pharmacopeial or regional expectations. I do not recommend approving a material solely because its name matches Crospovidone XL 10. A complete qualification package should include traceability, manufacturing information, change-notification procedures, and representative batch documentation where available.
The first step is to define the intended use: immediate-release tablet, orally disintegrating tablet, direct compression, wet granulation, or another application. Next, identify the critical quality attributes, such as disintegration time, dissolution profile, tablet hardness, friability, flow, and content uniformity. Only after these requirements are clear should the buyer compare price, minimum order quantity, and delivery schedule.
I also recommend requesting a sample for laboratory or pilot-scale evaluation. The trial should compare at least two or more addition levels and, where relevant, different addition locations in the process. For example, a buyer may assess 1%, 2%, and 5% w/w during screening, then select the lowest level that meets the finished-tablet requirements without creating unacceptable effects on flow, compression, or cost.
A dependable supplier should be able to explain product specifications, packaging, storage, batch traceability, and complaint handling. Buyers should ask how the supplier manages raw-material changes, specification revisions, and nonconforming batches. These questions are particularly important for pharmaceutical projects that require repeatable quality across development, validation, and routine production.
At Yuking, I support B2B buyers by discussing the intended tablet process, required documentation, sample evaluation, packaging needs, and export coordination for Crospovidone XL 10. I avoid treating one specification as suitable for every customer, because the correct grade and usage level must match the formulation and quality system. Product availability, documentation scope, and lead time should be confirmed for the specific order before procurement decisions are finalized.
Crospovidone XL 10 is not automatically the best disintegrant for every tablet. Highly hydrophobic formulations, excessive lubricant levels, high compression force, and poorly wettable active ingredients may limit the benefit of any superdisintegrant. In addition, a rapid disintegration result does not prove that the formulation will meet its dissolution or stability requirements.
Storage and handling also deserve attention. The material should be kept in the supplier’s recommended packaging and environmental conditions, with controls designed to reduce exposure to moisture and contamination. Before scale-up, the development team should confirm blend uniformity, compression behavior, disintegration, dissolution, friability, assay, and stability using the final process.
Crospovidone XL 10 is used mainly as a superdisintegrant to help pharmaceutical tablets break apart after contact with liquid. Its main value is supporting rapid tablet disintegration in immediate-release and selected fast-disintegrating formulations, while allowing the active ingredient to proceed toward dissolution. A practical starting range may be 1% to 5% w/w, but the final level and addition method must be established through product-specific testing.
For the next step, I suggest defining your tablet type, manufacturing process, target disintegration and dissolution requirements, expected annual volume, and documentation needs. Then request a current Crospovidone XL 10 specification, certificate of analysis, sample, packaging information, and commercial quotation from Yuking. This approach helps you evaluate technical suitability and supply reliability together before moving to pilot production or routine purchasing.
Contact us to discuss your requirements of crospovidone xl 10. Our experienced sales team can help you identify the options that best suit your needs.
Comments
Please Join Us to post.
0